AI in Healthcare: How Artificial Intelligence Is Changing Medicine

In 2020, DeepMind’s AlphaFold solved a problem that had stumped structural biologists for 50 years: predicting the 3D shape of proteins from their amino acid sequence. The ability to predict protein structure is fundamental to understanding disease and developing drugs. What had been the work of decades per protein could now be done in minutes, for all known proteins simultaneously.

This was not an incremental improvement. It was a step change in what is scientifically possible. And it is one of dozens of similarly significant AI-driven advances reshaping medicine and healthcare in the 2020s. This guide explains the key areas where AI is having real impact on medicine, the evidence behind the claims, and the genuine challenges that remain.

Medical Imaging and Diagnostics

Reading medical scans — X-rays, MRIs, CT scans, retinal photos — is one of the most proven applications of AI in medicine. AI models trained on millions of labelled images have demonstrated diagnostic accuracy equal to or exceeding specialist radiologists on specific tasks.

Google’s DeepMind AI, trained on retinal scans from Moorfields Eye Hospital in London, matched or exceeded the performance of the UK’s leading ophthalmologists at detecting over 50 eye diseases. An AI developed by Google Health and tested on mammography datasets reduced both false negatives (missed cancers) and false positives (unnecessary biopsies) compared to radiologists working alone.

In the NHS, AI tools are being deployed to triage chest X-rays, prioritise urgent CT scans, and assist radiologists with reporting. These tools do not replace the radiologist but augment their capacity — allowing the same workforce to process more scans at higher accuracy.

Drug Discovery and Development

Drug development is extraordinarily expensive and slow: approximately £2 billion and 12 years to bring a new drug to market, with a high failure rate. AI is being applied at multiple stages to reduce this cost and time.

AlphaFold’s protein structure database (released free by DeepMind for all known proteins) has already generated thousands of research papers and accelerated drug discovery across multiple disease areas. Molecular simulation and generative chemistry AI tools can propose novel drug candidates with specific target properties — a task that previously required years of laboratory iteration.

Insilico Medicine used AI to design and advance a new drug for idiopathic pulmonary fibrosis from concept to Phase II clinical trial in 4.5 years — significantly faster than the industry average. Recursion Pharmaceuticals uses AI to run millions of cellular biology experiments per week in automated laboratories, generating biological insight at a scale impossible through traditional approaches.